文献速递流行病学与生物统计

糖尿病前期与心血管疾病及全因死亡风险的关联:系统综述与Meta分析

Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2016-11-23

该系统综述与Meta分析纳入53项前瞻性队列研究、共1 611 339人,中位随访9.5年。结果发现,与血糖正常相比,糖耐量受损、空腹血糖受损(ADA或WHO标准)及HbA1c升高均与复合心血管疾病和冠心病风险增加相关,其中糖耐量受损还与全因死亡风险增加相关。

要点

  • 糖尿病前期(糖耐量受损、空腹血糖受损或HbA1c升高)与心血管疾病风险增加相关。
  • 空腹血糖低至5.6 mmol/L或HbA1c达39 mmol/mol时健康风险可能已增加。
  • 不同糖尿病前期定义对卒中及全因死亡风险的关联存在差异。

核心结论

  • 糖尿病前期(定义为糖耐量受损、空腹血糖受损或HbA1c升高)与心血管疾病风险增加相关。
  • 空腹血糖低至5.6 mmol/L或HbA1c达39 mmol/mol的人群健康风险可能增加。

研究设计与样本

  • 设计为前瞻性队列研究的Meta分析,检索PubMed、Embase和Google Scholar数据库。
  • 纳入53项来自一般人群的前瞻性队列研究,共1 611 339人,中位随访9.5年。

主要发现

  • 与血糖正常相比,空腹血糖受损(ADA标准)、空腹血糖受损(WHO标准)和糖耐量受损的复合心血管疾病相对风险分别为1.13、1.26和1.30。
  • 与血糖正常相比,上述三种糖尿病前期定义的冠心病相对风险分别为1.10、1.18和1.20,卒中相对风险分别为1.06、1.17和1.20。
  • 与血糖正常相比,空腹血糖受损(ADA标准)、空腹血糖受损(WHO标准)和糖耐量受损的全因死亡相对风险分别为1.13、1.13和1.32。
  • HbA1c升至39-47 mmol/mol或42-47 mmol/mol均与复合心血管疾病风险增加相关(相对风险分别为1.21和1.25)及冠心病风险增加相关(相对风险分别为1.15和1.28),但与卒中及全因死亡风险增加无关。

关键数值与推荐

  • 糖尿病前期定义:空腹血糖受损(ADA标准)为空腹血糖5.6-6.9 mmol/L;空腹血糖受损(WHO标准)为空腹血糖6.1-6.9 mmol/L;糖耐量受损为口服葡萄糖耐量试验2小时血浆葡萄糖7.8-11.0 mmol/L;HbA1c升高为39-47 mmol/mol(5.7-6.4%,ADA标准)或42-47 mmol/mol(6.0-6.4%,NICE指南)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate associations between different definitions of prediabetes and the risk of cardiovascular disease and all cause mortality. DESIGN: Meta-analysis of prospective cohort studies. DATA SOURCES: Electronic databases (PubMed, Embase, and Google Scholar). SELECTION CRITERIA: Prospective cohort studies from general populations were included for meta-analysis if they reported adjusted relative risks with 95% confidence intervals for associations between the risk of composite cardiovascular disease, coronary heart disease, stroke, all cause mortality, and prediabetes. REVIEW METHODS: Two authors independently reviewed and selected eligible studies, based on predetermined selection criteria. Prediabetes was defined as impaired fasting glucose according to the criteria of the American Diabetes Association (IFG-ADA; fasting glucose 5.6-6.9 mmol/L), the WHO expert group (IFG-WHO; fasting glucose 6.1-6.9 mmol/L), impaired glucose tolerance (2 hour plasma glucose concentration 7.8-11.0 mmol/L during an oral glucose tolerance test), or raised haemoglobin A1c (HbA1c) of 39-47 mmol/mol : (5.7-6.4%) according to ADA criteria or 42-47 mmol/mol (6.0-6.4%) according to the National Institute for Health and Care Excellence (NICE) guideline. The relative risks of all cause mortality and cardiovascular events were calculated and reported with 95% confidence intervals. RESULTS: 53 prospective cohort studies with 1 611 339 individuals were included for analysis. The median follow-up duration was 9.5 years. Compared with normoglycaemia, prediabetes (impaired glucose tolerance or impaired fasting glucose according to IFG-ADA or IFG-WHO criteria) was associated with an increased risk of composite cardiovascular disease (relative risk 1.13, 1.26, and 1.30 for IFG-ADA, IFG-WHO, and impaired glucose tolerance, respectively), coronary heart disease (1.10, 1.18, and 1.20, respectively), stroke (1.06, 1.17, and 1.20, respectively), and all cause mortality (1.13, 1.13 and 1.32, respectively). Increases in HBA1c to 39-47 mmol/mol or 42-47 mmol/mol were both associated with an increased risk of composite cardiovascular disease (1.21 and 1.25, respectively) and coronary heart disease (1.15 and 1.28, respectively), but not with an increased risk of stroke and all cause mortality. CONCLUSIONS: Prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA1c, was associated with an increased risk of cardiovascular disease. The health risk might be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or HbA1c of 39 mmol/mol.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016. PMID: 27881363. doi:10.1136/bmj.i5953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。